TAK-901
TAK-901 is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
Product Specifications
CAS Number
934541-31-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Aurora Kinase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/TAK-901.html
Purity
99.84
Solubility
DMSO : 65 mg/mL (ultrasonic)
Smiles
O=C(NC1CCN(CC1)C)C2=C(C3=C(C4=CC(C)=CN=C4N3)C(C5=CC=CC(S(=O)(CC)=O)=C5)=C2)C
Molecular Formula
C28H32N4O3S
Molecular Weight
504.64
Precautions
H302, H315, H319, H335
References & Citations
[1]Farrell P, et al. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Mol Cancer Ther. 2013 Apr;12 (4) :460-70.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Aurora A; Aurora B
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
248448-PE 100 µL
MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7, Jnkk2, MAPKK7, MKK7, PRKMK7) (PE)
Sign In for Pricing
View Details NBP2-89408F 0.1 mL
Rabbit Monoclonal Flt-3 Ligand/FLT3L Antibody (008) [FITC]
Sign In for Pricing
View Details